Abemaciclib in Newly Diagnosed Meningioma Patients

This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy. This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.

NCT Number	NCT05940493
Lead Sponsor	Nader Sanai Collaborators: Eli Lilly and Company, Barrow Neurological Institute, Ivy Brain Tumor Center
Conditions	Meningioma
Enrollment	72 participants
Start Date	2025-03-24
Primary Completion	2028-09 (estimated)
Study Completion	2030-09 (estimated)
Updated on ClinicalTrials.gov	2026-03-13